Renal safety of iodixanol

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 5, 2006, Pages 655-661

  McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Angiography; Chronic kidney disease; Contrast induced nephropathy; Iodinated contrast agent; Iso osmolar

Indexed keywords

DIATRIZOATE; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXILAN; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE;

ANGIOCARDIOGRAPHY; BRAIN ANGIOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; DRUG SAFETY; DRUG STRUCTURE; FEMORAL ANGIOGRAPHY; HEART DISEASE; HUMAN; INTERVENTIONAL RADIOLOGY; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SPECIALIST; META ANALYSIS; NEPHROTOXICITY; OSMOLARITY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK REDUCTION; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW;

CONTRAST MEDIA; HUMANS; KIDNEY DISEASES; OSMOLAR CONCENTRATION; RISK; TRIIODOBENZOIC ACIDS;

EID: 33750933483     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.5.655     Document Type: Review

References (18)

1. Morcos SK. Contrast media-induced nephrotoxicity-questions and answers. Br. J. Radiol. 71, 357-365 (1998).
2. Lindholt JS. Radiocontrast induced nephropathy. Eur. J. Vasc. Endovasc. Surg. 25, 296-304 (2003).
3. Brinker J. What every cardiologist should know about intravascular contrast. Rev. Cardiovasc. Med. 4 (Suppl. 5), S19-S27 (2003).
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 39, 930-936 (2002).
5. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med. 103, 368-375 (1997).
6. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275, 1489-1494 (1996).
7. Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am. J. Med. 83, 65-71 (1987).
8. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am. J. Med. 74, 243-248 (1983).
9. Guitterez N, Diaz A, Timmis GC, O'Neill WW, Stevens MA, McCullough PA. Determinants of serum creatinine trajectory in acute contrast nephropathy. J. Interv. Cardiol. 15(5), 349-354 (2002).
10. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur. Radiol. 9, 1602-1613 (1999).
11. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am. J. Med. 89, 615-620 (1990).
12. Deray G, Bellin MF, Boulechfar H et al. Nephrotoxicity of contrast media in high-risk patients with renal insufficiency: comparison of low- and high-osmolar contrast agents. Am. J. Nephrol. 11, 309-312 (1991).
13. Dawson P, Howell M. The non-ionic dimers: a new class of contrast agents. Br. J. Radiol. 59, 987-991 (1986).
14. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br. J. Radiol. 72, 701-703 (1999).
15. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N. Engl. J. Med. 348, 491-499 (2003).
16. McCullough PA, Bertrand ME, Brinker J, Stacul F. Contrast-induced nephropathy (CIN) following iso-osmolar (IOCM) versus low-osmolar contrast media (LOCM) in patients undergoing angiography and predicting factors for CIN: a meta-analysis. Eur. Radiol. 2004, B-934 (2003).
17. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int. 68(5), 2256-2263 (2005).
18. Lim P, Mackie K, Ross J, Seidelin P, Dzavik V. Contrast nephropathy and visipaque use in routine clinical practice of percutaneous coronary intervention: insights from Toronto General Hospital PCI registry. Presented at AHA Scientific Sessions. New Orleans, LA, USA 7-10 November 2004.